Department of Endocrinology and Metabolism, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
PLoS One. 2023 Aug 24;18(8):e0289616. doi: 10.1371/journal.pone.0289616. eCollection 2023.
To uncover the effect of GLP-1 receptor agonists (GLP-1 RAs) on the visceral- and hepatic fat content of adults.
PubMed, EMBASE, Cochrane Library, and Web of Science were searched from inception until November 2022. Randomized controlled trials (RCTs) of GLP-1Ras was extracted, including reports of effects on visceral adipose tissue and hepatic fat content in individuals with type 2 diabetes, non-type 2 diabetes, NAFLD (non-alcoholic fatty liver disease), and non-NAFLD. Meta-analyses used random-effects models.
1736 individuals in the 30 qualified RCTs were included, comprising 1363 people with type 2 diabetes and 318 with NFLD. GLP-1 RAs reduced visceral adipose tissue (standard mean difference [SMD] = -0.59, 95% CI [-0.83, -0.36], P<0.00001) and hepatic fat content (weighted mean difference [WMD] = -3.09, 95% CI [-4.16, -2.02], P<0.00001) compared to other control treatment. Subgroup analysis showed that GLP-1Ras dramatically decreased visceral fat in patients with type 2 diabetes (SMD = -0.49, 95% CI [-0.69, -0.29] P<0.00001), NAFLD (SMD = -0.99, 95% CI [-1.64, -0.34] P = 0.003), non-type 2 diabetes (SMD = -1.38, 95% CI [-2.44, -0.32] P = 0.01), and non-NAFLD (SMD = -0.53, 95% CI [-0.78, -0.28] P<0.0001). GLP-1Ras reduced the liver fat level of type 2 diabetes (WMD = -3.15, 95% CI [-4.14, -2.15] P<0.00001), NAFLD (WMD = -3.83, 95% CI [-6.30, -1.37] P = 0.002), and type 2 diabetes with NAFLD (WMD = -4.27, 95% CI [-6.80, -1.74] P = 0.0009), while showed no impact on the hepatic fat content in non-Type 2 diabetes (WMD = -12.48, 95% CI [-45.19, 20.24] P = 0.45).
LP-1 RAs significantly reduce visceral- and liver fat content in adults.
探讨胰高血糖素样肽-1 受体激动剂（GLP-1 RAs）对成年人内脏脂肪和肝内脂肪含量的影响。
检索PubMed、EMBASE、Cochrane 图书馆和 Web of Science 自成立至 2022 年 11 月的文献，提取 GLP-1Ras 的随机对照试验（RCTs），包括 2 型糖尿病、非 2 型糖尿病、非酒精性脂肪性肝病（NAFLD）和非 NAFLD 个体内脏脂肪组织和肝内脂肪含量影响的报告。采用随机效应模型进行荟萃分析。
30 项合格 RCT 中纳入 1736 名个体，包括 1363 名 2 型糖尿病患者和 318 名 NAFLD 患者。与其他对照组相比，GLP-1 RAs 可降低内脏脂肪组织（标准均数差 [SMD] = -0.59，95%CI [-0.83，-0.36]，P<0.00001）和肝内脂肪含量（加权均数差 [WMD] = -3.09，95%CI [-4.16，-2.02]，P<0.00001）。亚组分析显示，GLP-1Ras 可显著降低 2 型糖尿病患者的内脏脂肪（SMD = -0.49，95%CI [-0.69，-0.29]，P<0.00001）、NAFLD（SMD = -0.99，95%CI [-1.64，-0.34]，P = 0.003）、非 2 型糖尿病（SMD = -1.38，95%CI [-2.44，-0.32]，P = 0.01）和非 NAFLD（SMD = -0.53，95%CI [-0.78，-0.28]，P<0.0001）患者的内脏脂肪水平。GLP-1Ras 降低了 2 型糖尿病患者的肝脏脂肪水平（WMD = -3.15，95%CI [-4.14，-2.15]，P<0.00001）、NAFLD（WMD = -3.83，95%CI [-6.30，-1.37]，P = 0.002）和合并 NAFLD 的 2 型糖尿病患者（WMD = -4.27，95%CI [-6.80，-1.74]，P = 0.0009）的肝脏脂肪含量，但对非 2 型糖尿病患者的肝脏脂肪含量无影响（WMD = -12.48，95%CI [-45.19，20.24]，P = 0.45）。
LP-1 RAs 可显著降低成年人的内脏脂肪和肝内脂肪含量。
